苯那普利抗蛋白尿疗效与血管紧张素转换酶基因多态性的相关性

Relationship of angiotensin-converting enzyme gene polymorphism with the anti-proteinuria efficacy of benazepril

目的探讨苯那普利治疗原发性慢性肾小球肾炎蛋白尿的疗效与血管紧张素转换酶(ACE)基因多态性的相关性。方法用苯那普利治疗99例伴有蛋白尿的原发性慢性肾小球肾炎患者,治疗时间为3个月。用PCR方法检测ACE基因16内含子的I/D多态性,比较苯那普利治疗前后各基因型患者尿蛋白定量下降程度的差异。结果苯那普利治疗3月后,DD、DI型组的尿蛋白定量下降幅度明显高于II型组(P<0.05)。结论苯那普利可改善原发性慢性肾小球肾炎患者的尿蛋白,且与患者ACE基因型有明显相关性。

Objective To investigate the association between angiotensin- converting enzyme （ACE） gene polymorphism with the reducing urinary protein efficacy of benazepril in patients with primary chronic glomerulonephritis, Methods Ninety- nine primary glomerulonephritis patients with urinary protein were enrolled in this study, They were treated with benazepril for 3 months, The ACE gene I/D polymorphrism in 16 intron were determined by polymerase chain reaction. The reducing urinary protein efficacy of benazepril was compared with those different ACE genotype, Results After treatment of benazepril for 3 months, the rate of urinary protein decline were observed, The rate of reduction of proteinuria in patients with DD and DI genotype was obviously higher than that in Ⅱ genotype （ P 〈 0.05 ）, Conclusion Benazepril can declined the rate of umiary protein excretion in patients with primary chronic glomerulonephritis, and there was significantly relationship between ACE gene polymorphism and the reducing urinary protein efficacy of benazepril.